Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Intracranial activity of selpercatinib in RET fusion positive NSCLC

Vivek Subbiah • 25 May 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Selpercatinib
LIBRETTO-001

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, described the LIBRETTO-001 study (NCT03157128), a phase I/II study of selpercatinib, a RET inhibitor, in patients with RET fusion positive NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Vivek Subbiah

1:17
What role does germline genetic testing have in diagnosing cancer?
Vivek Subbiah • 17 Apr 2023
1:19
Phase I/II trial of EP0031, a next generation selective RET inhibitor
Vivek Subbiah • 17 Apr 2023
0:59
What does the future hold for precision medicine in oncology?
Vivek Subbiah • 17 Apr 2023
1:04
Highlights from AACR 2022
Vivek Subbiah • 11 Apr 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals